TrialRMD open2024

Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.

Maya H Buch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.